Bispecific antibody for desensitization in sensitized kidney transplant candidates
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial tests a new drug called a BiTE (a type of immunotherapy) to lower very high antibody levels in people waiting for a kidney transplant. If successful, it might help you become eligible for a transplant sooner.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have end-stage kidney disease and are on the kidney transplant waiting list.
- Your cPRA is 90% or higher and you've been waiting for a kidney for at least 5 years.
- You've already tried one or more standard desensitization treatments (like IVIG or plasmapheresis, possibly with rituximab) but your antibodies are still too high.
- Your major organs (like heart, lungs, and liver) are healthy enough to handle the study treatment.
- You are not pregnant or breastfeeding, and you agree to use contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a special immune-resetting treatment can help patients who have developed too many antibodies against donor kidneys get access to a compatible kidney transplant. The treatment uses chemotherapy and stem cell transplantation to 'reset' your immune system so it stops rejecting potential donor kidneys.
This study tests a new treatment called BiTE (a type of immunotherapy that helps your immune cells attack harmful antibodies) for people whose transplanted kidney is being damaged by chronic active antibody-mediated rejection. The goal is to see if it can safely slow or stop this damage.
This study tests whether a medication called belimumab can help people who are highly sensitized (their immune system has many antibodies against donor organs) become eligible for kidney transplant by improving how doctors understand their antibody patterns. The goal is to help these patients access transplants more easily.
This trial tests a new medicine called imlifidase that quickly removes harmful antibodies from the blood. It is given to children before a kidney transplant to make the donated kidney more likely to be accepted, especially when standard desensitisation methods have failed.
This study tests a new combination of drugs (an antibody called CD38 mAb plus azathioprine) to treat a type of chronic rejection that can happen months or years after a kidney transplant. The goal is to see if it can help stabilize or improve kidney function and prevent further damage.
This trial tests a new CAR-T therapy that targets immune cells to reduce harmful antibodies in highly sensitized kidney transplant candidates. The goal is to help your body accept a kidney from a donor that would otherwise be rejected.
Hear when a new Kidney Transplantation Recipients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.